newsfilter
← Latest News
GlobeNewswire·

Vericel Reports Third Quarter 2024 Financial Results

Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference